HS Code:
Antiprotozoals (excluding goods described in subheading note 2 to this chapter) fall under the Harmonized System (HS) Code 3004.90, which includes medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, specifically targeting protozoal infections such as malaria, leishmaniasis, and trypanosomiasis. These pharmaceutical products are critical in global health, particularly in tropical and subtropical regions where protozoal diseases are prevalent. This category encompasses a range of drugs, including artemisinin-based therapies for malaria, and other antiprotozoal agents used in both human and veterinary medicine.
Total Trade Volume
Approximately $3.2 billion USD
Data from 2022
Source
United Nations Comtrade Database, World Trade Organization (WTO) Reports
$1.1 billion USD
34.4% of total trade of total trade
Increasing
$650 million USD
20.3% of total trade of total trade
Stable
$450 million USD
14.1% of total trade of total trade
Increasing
$300 million USD
9.4% of total trade of total trade
Stable
$250 million USD
7.8% of total trade of total trade
Increasing
Average Rate
5.2% ad valorem
Highest Rate
12% (applied by certain developing countries to protect domestic pharmaceutical industries)
Lowest Rate
0% (under free trade agreements or for humanitarian aid programs)
Rising demand for malaria treatments
Increased export volumes from India and China due to high prevalence of malaria in Sub-Saharan Africa and Southeast Asia, driving innovation in affordable generics.
2021-2022
Shift toward combination therapies
Growing trade in artemisinin-based combination therapies (ACTs) as recommended by WHO, leading to higher R&D investments by major exporters like Switzerland.
2020-2022
Impact of global health initiatives
Programs like the Global Fund to Fight AIDS, Tuberculosis, and Malaria have boosted imports in low-income countries, often under zero-tariff schemes.
2019-2022
The World Health Organization approved a new artemisinin derivative formulation in 2022, developed by a Swiss pharmaceutical company, aimed at combating drug-resistant malaria strains.
October 2022
Expected to increase trade volumes from Switzerland and potentially shift market shares as demand for advanced formulations rises.
India introduced a new export incentive scheme for generic pharmaceuticals, including antiprotozoals, to boost production and competitiveness in the global market.
March 2023
Likely to solidify Indiaโs position as the leading exporter, with a projected 10% increase in trade volume over the next two years.
The African Union launched a program to encourage local production of antiprotozoal drugs in African countries, supported by technology transfers from major exporters.
June 2023
May reduce import dependency in the long term, potentially affecting trade volumes from top exporters like India and China.